GLPwatch
Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond.
Expert Rev Clin Pharmacol · 2024
Last updated 2026-05-28Tirzepatide is a new medication for diabetes that works differently from older drugs by targeting two hormones instead of one. In clinical trials, it improved blood sugar control and helped people lose weight, with doses ranging from 5 mg to 15 mg. It may also benefit conditions like obesity and heart disease, but side effects and risks—such as allergic reactions—require careful monitoring.
AI summary of the abstract below.
| Journal | Expert Rev Clin Pharmacol, 2024 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.34 |
| NIH percentile | 21 |
| Molecules | tirzepatide |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction |
Abstract
INTRODUCTION: Diabetes is a global public health challenge with rising prevalence. This review explores current diabetes understanding, diagnostic and management guidelines, economic impact, and lifestyle modifications as the primary approach.
AREAS COVERED: Focusing on pharmacological interventions, we discuss the roles of GLP-1 agonists and GLP/GIP agonists in diabetes management and cardiovascular risk reduction. Tirzepatide, a novel medication, is highlighted for its unique mechanism of action. Clinical trials demonstrate its effectiveness in glucose control, weight reduction, and its potential impact on diabetes, obesity, NASH, and cardiovascular risks.
EXPERT OPINION: Tirzepatide shows promise in diabetes treatment, offering glucose control and weight loss. It also holds potential for addressing comorbidities. However, cautious use is vital due to potential adverse effects and contraindications, including hypersensitivity reactions, pregnancy, and breastfeeding precautions. This review underscores tirzepatide as a valuable addition to diabetes therapies, with evolving prospects for enhanced patient outcomes as research advances.
Verbatim abstract via PubMed 38265050 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.